Ketorolac Versus Triamcinolone Knee Injections for Osteoarthritis

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Osteoarthritis is a disabling disease of the joint spaces and has a high impact on society due to the amount of people who are affected by the disease. Nonoperative management is a mainstay of therapy in most patients. Ketorolac tromethamine and triamcinolone acetonide intra-articular knee injections will be compared in a prospective, double-blinded, randomized trial in subjects with knee osteoarthritis. Subjects will be enrolled from the Orthopaedics Clinic based on inclusion and exclusion criteria. Intra-articular knee injection of ketorolac tromethamine or triamcinolone acetonide will be performed under ultrasound guidance. Multiple outcome measures will be performed throughout the six month period of follow-up. The investigators predict ketorolac tromethamine will have a longer duration of pain relief when compared to triamcinolone acetonide. The investigators predict there will be no differences between the two intra-articular knee injections in terms of function using validated scoring instruments.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: San Antonio Military Medical Center
• Treatments: Ketorolac; Ketorolac Tromethamine; Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Subject must be at least 18 years of age and no older than 90 years of age; of either gender

• Radiographic evidence of symptomatic osteoarthritis in one or bilateral knees. Osteoarthritis will be defined as pain with weight-bearing at the tibiofemoral and/or patellofemoral articulation together with radiographic findings as described below.

At the painful articulation, radiographic evidence of Kellgren-Lawrence

• Grade 2: definite osteophytes and possible narrowing of joint cartilage associated with sclerosis of subchondral bone or,

• Grade 3: moderate multiple osteophytes, definite narrowing of the joint space, small pseudocystic areas with sclerotic walls in the subchondral bone, possible deformity of bone ends or,

• Grade 4: large osteophytes, marked narrowing of joint space, severe sclerosis and altered shape of the bone ends.

Subject agrees to participate in follow-up evaluations and complete outcome score sheets (post-injection, 2 weeks, 6 weeks, 3 months and 6 months).

Exclusion Criteria:

• Any inflammatory or neuropathic arthropathy

• Insufficiency of the collateral ligaments or cruciate ligaments

• Current infection

• Recent injection (<3 months)

• Pregnant/lactating (β-human chorionic gonadotropin pregnancy test will be completed prior to injection)

• Allergy or hypersensitivity to the study medications

• Currently taking any anti-coagulation medications

• Subject is unable to make his/her own decision regarding the informed consent

• Subject is unable to read/understand English